Medicinal Chemistry Research

, Volume 28, Issue 12, pp 2200–2217 | Cite as

Microwave-assisted synthesis of 11-substituted-3,3-dimethyl-2,3,4,5,10,11-hexahydrodibenzo[b,e][1,4]diazepin-1-one derivatives catalysed by silica supported fluoroboric acid as potent antioxidant and anxiolytic agents

  • Kavita Bhagat
  • Atamjit Singh
  • Suruchi Dhiman
  • Jatinder Vir Singh
  • Ramandeep Kaur
  • Gurinder Kaur
  • Harmandeep Kaur Gulati
  • Palwinder Singh
  • Raman Kumar
  • Rajan Salwan
  • Kajal Bhagat
  • Harbinder SinghEmail author
  • Sahil SharmaEmail author
  • Preet Mohinder Singh BediEmail author
Original Research


Keeping in view the successive attributes of benzodiazepines on the central nervous system, we have synthesized a novel series of benzodiazepine derivatives as antioxidant and anxiolytic agents. All the compounds were obtained in good yield by facile synthesis. To check their antioxidant potential, DPPH (2,2-diphenyl-1-picrylhydrazyl) free radical scavenging assay was performed. Among all the synthetics seven derivatives (SD-3, SD-5, SD-7, SD-14, SD-18, SD-19, and SD-20) exhibited IC50 values ranging from 76 to 489 nM. These seven compounds were further evaluated to check their binding abilities towards the benzodiazepine binding site on GABAA receptors. Three best-fit ligands (SD-3, SD-14 and SD-20) were further evaluated for their anxiolytic effect by using three in vivo mice models i.e. Elevated Plus Maze, Light & Dark box, and Mirror Chamber model. The study revealed that compounds SD-3 and SD-20 showed the best anxiolytic effect as compared to standard drug diazepam even at an oral dose of 1.0 mg/kg.


Benzodiazepines Antioxidant activity Molecular modelling studies In silico studies In vivo anxiolytic effect 



The authors are grateful to University Grants Commission (RGNF), Council of Scientific & Industrial Research (CSIR), Department of Science & Technology (WOS-A) and DST-FIST for providing funds and are also thankful to Guru Nanak Dev University, Amritsar for providing various facilities to carry out the research work.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

44_2019_2447_MOESM1_ESM.docx (1.9 mb)
Supplementary Information


  1. Coassolo P, Aubert C (1985) Plasma determination of 3-methylclonazepam capillary gas chromatography. J Chromatogr 338:347–355PubMedGoogle Scholar
  2. Connor LC, Torrance HJ, McKeown DA (2016) ELISA detection of phenazepam, etizolam, pyrazolam, flubromazepam, diclazepam and delorazepam in blood using immunalysis benzodiazepine kit. J Anal Toxicol 40:159–161Google Scholar
  3. Constantinos GN, Constantinos AT, Julia SS, Christos AK, Dimitra JHL (2010) 1,5-benzoxazepines vs 1,5-benzodiazepines. One-pot microwave-assisted synthesis and evaluation for antioxidant activity and lipid peroxidation inhibition. J Med Chem 53:8409–8420Google Scholar
  4. Cortes EC, Ana LVC, Olivia GM (2007) New derivatives of dibenzo[b,e][1,4]diazepin-1-ones by an efficient synthesis and spectroscopy. J Heterocycl Chem 44:183–187Google Scholar
  5. Cottrell GA, Lambert JJ, Peters JA (1987) Modulation of GABAA receptor activity by alphaxalone. Br J Pharm 90:491–500Google Scholar
  6. Craske MG, Rauch SL, Ursano R, Prenoveau J, Pine DS, Zinbarg RE (2009) What is an anxiety disorder? Depress Anxiety 26:1066–1085PubMedGoogle Scholar
  7. Dean OM, Buuse M, Van Den Bush AI, Copolov DL, Ng F, Dodd S, Berk M (2009) A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? animal models and relevance to clinical practice. Curr Med Chem 16:2965–2976PubMedGoogle Scholar
  8. El-Balkhi S, Chaslot M, Picard N, Dulaurent S, Delage M, Mathieu O, Franck SM (2017) Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer. Int J Leg Med 131:979–988Google Scholar
  9. Evans BE, Rittle KE, Bock MG, Dipardo RM, Freidinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PS, Chang RSL, Lotti VJ, Cerino DJ, Chen TB, Kling PJ, Kunkel KA, Springer JP, Hirshfield J (1988) Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 31:2235–2246PubMedGoogle Scholar
  10. Gage SB, Pariente A, Bernard B (2015) Is there really a link between benzodiazepine use and the risk of dementia? Expert Opin Drug Saf 14:1–15Google Scholar
  11. Garibova TL, Voronina TA (1986) Characteristics and Mechanisms of Tolerance to Benzodiazepines. In: Valdman A.V. (eds). Drug Dependence and Emotional Behavior. Springer, Boston, MA. p. 468−471.Google Scholar
  12. Gray SL, Dublin S, Yu O, Walker R, Anderson M, Hubbard RA, Crane PK, Larson EB (2016) Benzodiazepine use and risk of incident dementia or cognitive decline: Prospective population based study. BMJ 352:352–390Google Scholar
  13. Horton DA, Bourne GT, Smythe ML (2003) The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem Rev 103:893–930PubMedGoogle Scholar
  14. National Institute of Mental. Accessed 25 Feb 2019
  15. Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S (2017) Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam. Forensic Toxicol 35:1–10PubMedGoogle Scholar
  16. Ko SH, Cao W, Liu Z (2010) Hypertension management and microvascular insulin resistance in diabetes. Curr Hypertens Rep 12:243–251PubMedPubMedCentralGoogle Scholar
  17. Krystal JH, Stossel S, Krystal AD (2015) Restricting benzodiazepines to short-term prescription. JAMA Psychiatry 72:2–3Google Scholar
  18. Lukasik GM, Sommerfeld K, Tezyk A, Zielinska PB, Panienski P, Zaba C (2016) Flubromazolam—a new life-threatening designer benzodiazepine. Clin Toxicol 54:66–68Google Scholar
  19. Michelini S, Cassano GB, Frare F, Perugi G (1996) Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry 29:127–134PubMedGoogle Scholar
  20. Makaron L, Moran CA, Namjoshi O, Rallapalli S, Cook JM, Rowlett JK (2013) Cognition-impairing effects of benzodiazepine-type drugs: role of GABAA receptor subtypes in an executive function task in rhesus monkeys. Pharm Biochem Behav 104:62–68Google Scholar
  21. Manchester KR, Maskell PD, Lomas EC, Waters L, Dempsey FC (2017) The Emergence of New Psychoactive Substance (NPS) benzodiazepines: a review. Drug Test Anal 10:1–17Google Scholar
  22. Manchester KR, Maskell PD, Waters L (2018) Experimental versus theoretical log D 7.4, pK a and plasma protein binding values for benzodiazepines appearing as new psychoactive substances. Drug Test Anal 10:1258–1269Google Scholar
  23. Maskell P, De PG, Seetohul N, Pounder D (2014) Phenazepam: the drug that came in from the cold. J Forensic Leg Med 19:122–125Google Scholar
  24. Masood A, Nadeem A, Mustafa SJ, O’Donnell JM (2008) Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice. J Pharm Exp Ther 2:369–379Google Scholar
  25. McLean MJ, Macdonald RL (1988) Benzodiazepines, but not beta carbolines, limit high frequency repetitive firing of action potentials of spinal cord neurons in cell culture. J Pharm Exp Ther 244:789–795Google Scholar
  26. Menezes CMS, Rivera G, Alves MA, Amaral DN, Thibaut JPB, Noel F, Eliezer JB, Lıdia ML (2012) Synthesis, biological evaluation, and structure−activity relationship of clonazepam, meclonazepam, and 1,4-benzodiazepine compounds with schistosomicidal activity. Chem Biol Drug Des 79:943–949PubMedGoogle Scholar
  27. Moosmann B, Bisel P, Auwarter V (2014) Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal 6:757–763PubMedGoogle Scholar
  28. Moosmann B, Hutter M, Huppertz LM, Ferlaino S, Redlingshofer L, Auwarter V (2013) Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicol 31:263–271Google Scholar
  29. Mortele O, Vervliet P, Gys C, Degreef M, Cuykx M, Maudens K, Adrian C, Alexander LN, Van N, Foon YL (2018) In vitro Phase I and Phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal 153:158–167PubMedGoogle Scholar
  30. Nash J, Nutt DJ (2004) Psychopharmacology of anxiety. Epidemiol Psychol Psychopharmacol 3:11−15.Google Scholar
  31. Nutt DJ, Malizia AL (2001) New insights into the role of the GABAA-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179:390–396PubMedGoogle Scholar
  32. Oliveira MR, Silvestrin RB, Souza TM, Moreira JCF (2007) Oxidative stress in the hippocampus, anxiety-like behavior and decreased locomotory and exploratory activity of adult rats: effects of sub acute vitamin A supplementation at therapeutic doses. Neurotoxicology 28:1191–1199PubMedGoogle Scholar
  33. Ookura R, Kito K, Ooi T, Namikoshi M, Kusumi T (2008) Structure revision of circumdatins A and B, benzodiazepine alkaloids produced by marine fungus Aspergillus ostianus, by X-ray crystallography. J Org Chem 73:4245–4247PubMedGoogle Scholar
  34. Pande G, Akoh CC (2009) Antioxidant capacity and lipid characterization of six Georgia-grown pomegranate cultivars. J Agric Food Chem 57:9427–9436PubMedGoogle Scholar
  35. Paradis S, Leoni V, Caccia C, Berdeaux A, Morin D (2013) Cardioprotection by the TSPO ligand 4’-chlorodiazepam is associated with inhibition of mitochondrial accumulation of cholesterol at reperfusion. Cardiovasc Res 98:420–427PubMedGoogle Scholar
  36. Pasquale GA, Ruiz DM, Jios JL, Autino JC, Romanelli GP (2013) Preyssler catalyst-promoted rapid, clean, and efficient condensation reactions for 3h-1,5-benzodiazepine synthesis in solvent-free conditions. Tetrahedron Lett 54:6574–6579Google Scholar
  37. Robertson MD, Drummer OH (1998) Stability of nitrobenzodiazepines in postmortem blood. J Forensic Sci 43:60–81Google Scholar
  38. Roesler R, Malta LG, Carrasco LC, Holanda RB, Sousa CAS, Pastore GM (2007) Antioxidant activity of cerrado fruits. Cienc Tecnol Aliment 27:53–60Google Scholar
  39. Salim S, Asghar M, Taneja M, Hovatta I, Chugh G, Vollert C, Vu A (2011) Potential contribution of oxidative stress and inflammation to anxiety and hypertension. Brain Res 1404:63–71PubMedPubMedCentralGoogle Scholar
  40. Salustri C, Squitti R, Zappasodi F, Ventriglia M, Bevacqua MG, Fontana M, Tecchio F (2010) Oxidative stress and brain glutamate-mediated excitability in depressed patients. J Affect Disord 127:321–325PubMedGoogle Scholar
  41. Simonas M, Rooma D, Tomasz U, Itziar SM, Duncan L, Dimple K, Tomas M, Jasenko Z, Els P, Abhay K, Jan S, Keith WMA, Radu A (2019) GABAA receptor signalling mechanisms revealed by structural pharmacology. Nature 565:454–459Google Scholar
  42. Skopp G, Potsh L, Mattern R (1998) A preliminary study on the stability of benzodiazepines in blood and plasma stored at 4° C. Int J Leg Med 111:1–5Google Scholar
  43. Sternbach LH, Fryer RI, Metlesics W, Reeder E, Stach G, Saucy G, Stempel A (1962) Quinazolines and 1,4-benzodiazepines. VI. Halo-, methyl-, and methoxy-substituted 1,3-dihydro-5-phenyl- 2H-1,4-benzodiazepin-2-ones. J Org Chem 27:3788–3796Google Scholar
  44. Tang HJ, Zhang XW, Yang L, Li W, Li JH, Wang JX, Chen J (2016) Synthesis and evaluation of xanthine oxidase inhibitory and antioxidant activities of 2-arylbenzo[b]furan derivatives based on salvianolic acid C. Eur J Med Chem 124:637–648PubMedGoogle Scholar
  45. Venkatakrishnan K, Culm KE, Ehrenberg BL, Harmatz JS, Corbett KE, Fleishaker JC, David JG (2005) Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. J Clin Pharm 45:529–537Google Scholar
  46. Wagner J, Wagner ML, Hening WA (1998) Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 32:680–691PubMedGoogle Scholar
  47. Wang G, Liu C, Li B, Wang Y, Hecke KV, Eycken EVV, Pereshivko OP, Peshkov VA (2017) Diversity-oriented synthesis of 1,3-benzodiazepines. Tetrahedron 73:6372–6380Google Scholar
  48. Wesolowski AM, Zaccagnino MP, Malapero RJ, Kaye AD, Urman RD (2016) Remimazolam: pharmacologic considerations and clinical role in anaesthesiology. Pharmacother 36:1021–1027Google Scholar
  49. Zizhao G, Chunlin Z, Lingjian Z, Yongqiang Z, Jianzhong Y, Guoqiang D, Shengzheng W, Yang L, Hai C, Chunquan Sh, Zhenyuan M, Wannian Z (2012) Structure−activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors. Eur J Med Chem 56:10–16Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical SciencesGuru Nanak Dev UniversityAmritsarIndia
  2. 2.University Institute of Pharmaceutical SciencesPanjab UniversityChandigarhIndia
  3. 3.Department of ChemistryGuru Nanak Dev UniversityAmritsarIndia

Personalised recommendations